News

Whitehead Institute Member Susan Lindquist has received the Max Delbrück Medal in Berlin, Germany, for her work on protein folding.

President Obama today named Whitehead Member Susan Lindquist a recipient of the National Medal of Science, the nation’s highest scientific honor.

As Whitehead Institute’s newest Fellow, Yaniv Erlich comes to Cambridge in search of rare genetic variants or mutations occurring in individual human genomes.

Whitehead Institute postdoctoral fellow Yaqub (Jacob) Hanna has been recognized as a 2010 Young Innovator by MIT's Technology Review magazine.

Mary Gehring will be studying epigenetic reprogramming in the model plant Arabidopsis thaliana. Her work has commonalities and potential synergies with research occurring in other Whitehead laboratories.

The genes that are responsible for maintaining each cell type form DNA loops that link control elements for these genes. This surprising genome structure is generated and reinforced by two essential protein complexes that bridge the loops and contribute to proper gene regulation.

Short pieces of RNA, called microRNAs, control protein production by causing the proteins’ RNA templates (known as messenger RNA or mRNA) to be disabled by the cell, according to Whitehead Institute scientists.

Cancer biologist Piyush Gupta joins the Whitehead Institute faculty in September on a mission to shed new light on the mechanisms that determine why some cells in our bodies behave appropriately while others venture down destructive, malignant paths.

Human embryonic stem (ES) cells and adult cells reprogrammed to an embryonic stem cell-like state—so-called induced pluripotent stem or iPS cells—exhibit very few differences in their gene expression signatures and are nearly indistinguishable in their chromatin state, according to Whitehead Institute researchers.

Researchers at Whitehead Institute and Children’s Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. High levels of Musashi 2 protein is associated with increased cell proliferation, decreased cell maturation, and multiple cancer-related cellular pathways in human leukemias.